Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TMCI Stock Forecast 2025-2026
$6.72
Current Price
$419.23M
Market Cap
Buy 2
Hold 5
Sell 0
Wall St Analyst Ratings
Distance to TMCI Price Targets
+138.1%
To High Target of $16.00
+48.8%
To Median Target of $10.00
+19.0%
To Low Target of $8.00
TMCI Price Momentum
+4.3%
1 Week Change
-20.5%
1 Month Change
-35.4%
1 Year Change
-9.7%
Year-to-Date Change
-40.7%
From 52W High of $11.33
+71.4%
From 52W Low of $3.92
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Treace Medical (TMCI) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on TMCI and similar high-potential opportunities.
Latest TMCI Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, TMCI has a neutral consensus with a median price target of $10.00 (ranging from $8.00 to $16.00). The overall analyst rating is Buy (7.1/10). Currently trading at $6.72, the median forecast implies a 48.8% upside. This outlook is supported by 2 Buy, 5 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Danielle Antalffy at UBS, projecting a 138.1% upside. Conversely, the most conservative target is provided by Richard Newitter at Truist Securities, suggesting a 19.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TMCI Analyst Ratings
2
Buy
5
Hold
0
Sell
TMCI Price Target Range
Low
$8.00
Average
$10.00
High
$16.00
Current: $6.72
Latest TMCI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TMCI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 11, 2025 | Truist Securities | Richard Newitter | Hold | Maintains | $8.00 |
| Mar 13, 2025 | Truist Securities | Richard Newitter | Hold | Maintains | $9.50 |
| Mar 3, 2025 | Truist Securities | Richard Newitter | Hold | Maintains | $10.00 |
| Dec 31, 2024 | Lake Street | Ben Haynor | Buy | Initiates | $14.50 |
| Dec 18, 2024 | Truist Securities | Hold | Maintains | $0.00 | |
| Nov 6, 2024 | Stifel | Rick Wise | Hold | Maintains | $8.00 |
| Oct 14, 2024 | Truist Securities | Richard Newitter | Hold | Maintains | $6.00 |
| Aug 7, 2024 | UBS | Danielle Antalffy | Neutral | Maintains | $7.00 |
| Aug 7, 2024 | Truist Securities | Richard Newitter | Hold | Maintains | $7.50 |
| Jul 16, 2024 | Truist Securities | Richard Newitter | Hold | Maintains | $9.00 |
| Jul 15, 2024 | Morgan Stanley | Drew Ranieri | Equal-Weight | Maintains | $8.00 |
| May 16, 2024 | UBS | Danielle Antalffy | Neutral | Downgrade | $6.50 |
| May 8, 2024 | BTIG | Ryan Zimmerman | Neutral | Downgrade | $0.00 |
| May 8, 2024 | Truist Securities | Richard Newitter | Hold | Downgrade | $7.00 |
| May 8, 2024 | UBS | Danielle Antalffy | Buy | Maintains | $16.00 |
| May 8, 2024 | Morgan Stanley | Drew Ranieri | Equal-Weight | Downgrade | $5.50 |
| May 8, 2024 | Stifel | Rick Wise | Hold | Downgrade | $6.00 |
| May 8, 2024 | JP Morgan | Robbie Marcus | Neutral | Downgrade | $8.00 |
| Dec 22, 2023 | Truist Securities | Richard Newitter | Buy | Maintains | $16.00 |
| Nov 13, 2023 | Morgan Stanley | Drew Ranieri | Overweight | Maintains | $14.00 |
Treace Medical Concepts Inc. (TMCI) Competitors
The following stocks are similar to Treace Medical based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
TMCI
Treace Medical
mkt cap
408.93M
Treace Medical Concepts Inc. (TMCI) Financial Data
Treace Medical Concepts Inc. has a market capitalization of $419.23M with a P/E ratio of -7.7x. The company generates $209.36M in trailing twelve-month revenue with a -26.6% profit margin.
Revenue growth is +10.4% quarter-over-quarter, while maintaining an operating margin of -0.2% and return on equity of -44.4%.
Valuation Metrics
Market Cap
$419.23M
Enterprise Value
$414.62M
P/E Ratio
-7.7x
PEG Ratio
-9.0x
Price/Sales
2.0x
Growth & Margins
Revenue Growth (YoY)
+10.4%
Gross Margin
+80.7%
Operating Margin
-0.2%
Net Margin
-26.6%
EPS Growth
+10.4%
Financial Health
Cash/Price Ratio
+18.0%
Current Ratio
4.6x
Debt/Equity
61.7x
ROE
-44.4%
ROA
-14.8%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Treace Medical Concepts Inc. (TMCI) Business Model
About Treace Medical Concepts Inc.
What They Do
Develops orthopedic medical devices for bunion correction.
Business Model
The company generates revenue primarily through the sale of its flagship product, the Lapiplasty 3D Bunion Correction System, to hospitals, surgeons, and healthcare providers. By focusing on innovative solutions that improve patient outcomes, Treace Medical Concepts builds strong relationships with medical professionals and enhances its market presence.
Additional Information
Headquartered in Ponte Vedra, Florida, Treace Medical Concepts has established a robust distribution network backed by sales representatives and medical partnerships across the United States. The company emphasizes research and technology in its product development, aiming to advance surgical techniques and establish itself as a key player in the healthcare and medical device sectors.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
477
CEO
Mr. John T. Treace
Country
United States
IPO Year
2021
Website
www.treace.comTreace Medical Concepts Inc. (TMCI) Latest News & Analysis
Latest News
Quick Summary
Rosen Law Firm alerts Treace Medical Concepts, Inc. (NASDAQ: TMCI) investors of a lead plaintiff deadline on June 10, 2025, for securities purchased between May 8, 2023, and May 7, 2024.
Why It Matters
The announcement signals potential legal issues for Treace Medical, which could affect its stock performance and investor confidence during the specified class period.
Source: GlobeNewsWire
Market Sentiment:
Neutral
TMCI Investors Have Opportunity to Lead Treace Medical Concepts, Inc. Securities Fraud Lawsuit
2 days ago
Quick Summary
Rosen Law Firm alerts Treace Medical Concepts, Inc. (TMCI) investors who bought shares between May 8, 2023, and May 7, 2024, of a June 10, 2025, lead plaintiff deadline for potential compensation.
Why It Matters
The announcement highlights a class action lawsuit for Treace Medical investors, potentially influencing stock price and investor sentiment, while offering a pathway for compensation.
Source: PRNewsWire
Market Sentiment:
Neutral
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Treace Medical
2 days ago
Quick Summary
Faruqi & Faruqi, LLP's James Wilson is urging investors who experienced losses with Treace Medical to reach out for a discussion on their legal options.
Why It Matters
The call for investors to discuss losses in Treace Medical signals potential legal action, which could impact stock prices and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Treace Medical Concepts (TMCI) will release its Q1 2025 financial results on May 8, 2025, after market close, followed by a conference call at 4:30 PM ET.
Why It Matters
Treace Medical's upcoming financial results release and conference call could indicate performance trends, influencing stock valuation and investor sentiment in the medical technology sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A class action lawsuit has been filed against Treace Medical Concepts, Inc. (TMCI) for alleged federal securities law violations during the period of May 8, 2023, to May 7, 2024.
Why It Matters
The class action lawsuit against Treace Medical could lead to financial liability, regulatory scrutiny, and stock price volatility, impacting investor confidence and potential returns.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A class action securities lawsuit has been filed against Treace Medical Concepts, Inc. (NASDAQ: TMCI), as announced by Levi & Korsinsky, LLP on April 24, 2025.
Why It Matters
The class action lawsuit against Treace Medical Concepts may lead to financial liability, affecting stock prices and investor confidence in the company.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About TMCI Stock
What is Treace Medical Concepts Inc.'s (TMCI) stock forecast for 2025?
Based on our analysis of 9 Wall Street analysts, Treace Medical Concepts Inc. (TMCI) has a median price target of $10.00. The highest price target is $16.00 and the lowest is $8.00.
Is TMCI stock a good investment in 2025?
According to current analyst ratings, TMCI has 2 Buy ratings, 5 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.72. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TMCI stock?
Wall Street analysts predict TMCI stock could reach $10.00 in the next 12 months. This represents a 48.8% increase from the current price of $6.72. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Treace Medical Concepts Inc.'s business model?
The company generates revenue primarily through the sale of its flagship product, the Lapiplasty 3D Bunion Correction System, to hospitals, surgeons, and healthcare providers. By focusing on innovative solutions that improve patient outcomes, Treace Medical Concepts builds strong relationships with medical professionals and enhances its market presence.
What is the highest forecasted price for TMCI Treace Medical Concepts Inc.?
The highest price target for TMCI is $16.00 from Danielle Antalffy at UBS, which represents a 138.1% increase from the current price of $6.72.
What is the lowest forecasted price for TMCI Treace Medical Concepts Inc.?
The lowest price target for TMCI is $8.00 from Richard Newitter at Truist Securities, which represents a 19.0% increase from the current price of $6.72.
What is the overall TMCI consensus from analysts for Treace Medical Concepts Inc.?
The overall analyst consensus for TMCI is neutral. Out of 9 Wall Street analysts, 2 rate it as Buy, 5 as Hold, and 0 as Sell, with a median price target of $10.00.
How accurate are TMCI stock price projections?
Stock price projections, including those for Treace Medical Concepts Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 28, 2025 10:03 PM UTC